Clinical Trial Detail

NCT ID NCT02599779
Title A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sunnybrook Health Sciences Centre
Indications

renal cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.